Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1

Status

Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Breast Neoplasms 102Carcinoma, Non-Small-Cell Lung 93Multiple Myeloma 80Prostatic Neoplasms 74Colorectal Neoplasms 59Neoplasms 57Leukemia, Myeloid, Acute 56Lymphoma 48Squamous Cell Carcinoma of Head and Neck 43Lung Neoplasms 39Ovarian Neoplasms 38Melanoma 38Neoplasm Metastasis 36Pancreatic Neoplasms 35Lymphoma, Non-Hodgkin 35Carcinoma, Hepatocellular 34Lymphoma, Large B-Cell, Diffuse 33Sarcoma 31Head and Neck Neoplasms 31Urinary Bladder Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Carcinoma, Renal Cell 29Leukemia, Lymphocytic, Chronic, B-Cell 28Hodgkin Disease 28Endometrial Neoplasms 28Triple Negative Breast Neoplasms 27Myelodysplastic Syndromes 26Recurrence 25Hematologic Neoplasms 25Glioma 25

Interventions

epigallocatechin gallate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Uterine Cervical Dysplasia × 30 days × Clear all
NCT07545746 2026-06-02

ASCEND

UNC Lineberger Comprehensive Cancer Center

Phase 2 Not yet recruiting
140 enrolled
Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, HIV Infections, Papillomavirus Infections

NCT06519994 2026-05-14

Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
120 enrolled
Gynecologic

Acquired Immunodeficiency Syndrome, Uterine Cervical Dysplasia

NCT07572396 2026-05-14

Phase II Study of Dysplasixâ„¢ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities

Amplexd Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia, Papillomavirus Infections, Atypical Squamous Cells of the Cervix

NCT07454915 2026-05-06

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

PapiVax Biotech, Inc.

Phase 2 Recruiting
138 enrolled
Gynecologic

Uterine Cervical Dysplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡